NSE · Healthcare · Medical Instruments & Supplies
EPS came in at 1.12 against a street estimate of 0.50 — a beat of 124.0%.
with an average price target of ₹690.00.
| Document | Date |
|---|---|
| Annual report FY2026 TARSONS PRODUCTS LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹3,329.31 Million (YoY growth from ₹3,141.77 | 2026-09-02 |
| Q1 FY27 earnings call TARSONS PRODUCTS LIMITED Q1 FY'27 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenue: Rs. 110.2 crores, up 20.7% Y-o-Y • Standalone revenue: R | 2026-08-17 |
| Investor presentation · Q1 FY27 TARSONS PRODUCTS LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Total Consolidated Revenue: ₹110.2 crs in Q1 FY27, up 21% YoY from ₹91.4 crs | 2026-08-11 |
| Quarterly results · Q1 FY27 TARSONS PRODUCTS LIMITED – Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q1 FY27): ₹1,102.42 million • Con | 2026-08-10 |
| Q4 FY26 earnings call TARSONS PRODUCTS LIMITED – Q4 & FY '26 SUMMARY HEADLINE NUMBERS • Q4 FY'26 standalone revenue: INR97 crores (4.4% YoY growth); FY'26 standalone reve | 2026-06-01 |
| Investor presentation · Q4 FY26 TARSONS PRODUCTS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Consolidated Revenue: ₹422.5 crores (FY25: ₹392.4 crores), growth of 8% Y-o-Y • | 2026-05-23 |
| Quarterly results · Q4 FY26 TARSONS PRODUCTS LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • FY 2025-26 Consolidated Revenue from Operations: ₹428.513 million • FY 2025-26 Consol | 2026-05-22 |
| Q3 FY26 earnings call TARSONS PRODUCTS LIMITED – Q3 & 9-MONTHS FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Standalone Revenue: INR 84 crores, up 12.8% YoY (consolidated: INR | 2026-02-11 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tarsons Products Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.